Public Workshop-medical devices and nano-technologies: industry, description, and identify istutteiden, 23. September 2010

This workshop is designed to obtain information to take advantage of nanotechnology, efficiency and safety of medical devices. Specifically, FDA would like to include public input or EU criminal justice area medical devices and Diagnostics nanostructures, including manufacture, a description, and istutteiden assessment. FDA seeks information on these topics and solicit comments on a number of issues.

This workshop will be held on 23.September 2010 at the latest 8 am 5 pm.

Public workshop has been manufactured, keep at the Hilton Washington DC/North Gaithersburg, Maryland, 620 Perry Pkwy, Gaithersburg, MD 20877. Direction, please contact the hotel (301) 977-8900, or refer to their Web site at: www.gaithersburg.hilton.com

Meeting Webcast.

Public Workshop on medical devices and nano-technologies: industry, description, and how to determine whether the draft Agenda istutteiden

Date: September 23

Location:Hilton Washington DC/North Gaithersburg, Maryland, 620 Perry Pkwy, Gaithersburg, MD 20877,

Welcome/design day and logistics Session I medical devices containing or tietoliikenneprotokollat EU criminal justice area or nanostructures (production characterization)

Administrator's introduction of the Session I

-Scientific/regulatory considerations for discussion – [questions discussion] list of CDRH

Medical devices containing or tietoliikenneprotokollat EU criminal justice area or nanostructures manufacture/characterization and quality control (QC) considerations for

Expert speaker presentation (s)

Session I Roundtable discussion Session II: improved electrochemical cells (batteries)/bio-distribution evaluation damp containing or tietoliikenneprotokollat EU criminal justice area or nanostructures 

Administrator's introduction of Session II

-Scientific/regulatory considerations for discussion – [questions discussion] list of CDRH

Istutteiden/toxicological considerations for medical devices containing or tietoliikenneprotokollat EU criminal justice area or nanostructures

Expert speaker presentation (s)

Session II Roundtable discussion

The persons concerned must be registered not later than 15 September 2010.

There is no registration fee public workshop. Early registration is recommended, because the seats is limited to the date on which the General seminar, shall be adopted in accordance with the registration of the days from the date of the space available at 7: 30

If you want to make oral presentation at the workshop of making known their views during the sessions (see paragraph (II) additional data FR notice), this must be stated during the registration. FDA request that presentations focus on additional data for FR notice areas defined in section III. What do you want to address your presentation to a discussion topic to be identified. each discussion topic at hand were concentrated in the open session to keep each oral presentation should be treated with only one topic. FDA will do its best to requests to speak. registered participants can send to the contact person of written material oral presentations 5 p.m. 15.September 2010.

If you want to participate in the two planned round-table discussions (see section II FOR additional data FR notice), show that advantage when the registration and shall also produce a brief statement that describes the experience and expertise with the nanotechnologies. number of participants Is johtamismenetelmiä. FDA attempts to be represented in this chat room "constituencies" different. other public workshop attendance is given the opportunity to listen to the discussion of each johtamismenetelmiä and to the public in the comments, time allows.

If you need special Accommodations, please contact disabilidád thanks to Susan 301-796-5661, at susan.monahan@fda.hhs.gov at Monahan of at least 7 days in advance of the meeting.

Daya Ranamukhaarachchi
The Director of the Center CDRH
10903 New Hampshire Avenue
WO-66, room 5574
Silver Spring, MD 20993
(301) 796-6155
(301) 847-8512-Fax
Daya.ranamukhaarachchi@fda.hhs.gov